<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320241</url>
  </required_header>
  <id_info>
    <org_study_id>320924197612177170-BS</org_study_id>
    <nct_id>NCT01320241</nct_id>
  </id_info>
  <brief_title>Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture</brief_title>
  <official_title>An Unicentric RCT About Novel Radiation Stent Versus Nitinol SEMS for Palliative Treatment of Malignant Biliary Stricture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant biliary obstruction is a common clinical condition caused by various malignancies.&#xD;
      Currently,biliary stent implantation guided either by fluoroscopy or endoscopy has become the&#xD;
      most important methods for relieving malignant biliary obstruction. However, the benefit for&#xD;
      the survival of the patients with palliation of the stent treatment is limited because no&#xD;
      therapeutic effects on process of the tumor itself by a stent implantation. Encouraged by the&#xD;
      success of 125I esophageal stent in esophageal carcinoma, a novel biliary stent loaded with&#xD;
      125I radioactive seeds has been developed in our institute. After ex vivo and in vivo&#xD;
      evaluations for the delivery system, the investigators prospectively compare the responses to&#xD;
      treatment with this radiation biliary stent, versus the conventional biliary SEMS in patient&#xD;
      with malignant biliary obstruction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Mean Survival and Median Survival</measure>
    <time_frame>follow-up in interval of stent insertion and death (3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Technical Success, Clinical Success, Safety (including WBC and Immunological changes of lab, Leakage of the radioactive seeds and Complications related to the procedure.</measure>
    <time_frame>follow-up in interval of stent insertion and death (3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cholangiocellular Carcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Metastatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>novel radiation stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo placement of a novel biliary stent loaded with 125I seeds on day 1.&#xD;
Intervention: Device: self-expandable 125I radioactive seeds-loaded-stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo placement of a conventional nitinol SEMS on day1.&#xD;
Intervention: Device: self-expandable biliary nitinol alloys stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>self-expandable 125I radioactive seeds-loaded-stent</intervention_name>
    <description>Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.</description>
    <arm_group_label>novel radiation stent</arm_group_label>
    <other_name>irradiation biliary stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>self-expandable biliary nitinol alloys stent</intervention_name>
    <description>Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.</description>
    <arm_group_label>conventional stent</arm_group_label>
    <other_name>conventional SEMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years old or older&#xD;
&#xD;
          -  Biliary obstruction by any malignant process with histologically or cytologically&#xD;
             confirmed by biopsy or previous surgical procedures&#xD;
&#xD;
          -  Clinical symptoms of biliary obstruction&#xD;
&#xD;
          -  Unresectable or refused to be surgically treated biliary obstruction by any malignant&#xD;
             process&#xD;
&#xD;
          -  Willing and able to comply with the study procedures and provide written informed&#xD;
             consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected benign bile duct stricture&#xD;
&#xD;
          -  Strictures that can not be dilated enough to pass the delivery system&#xD;
&#xD;
          -  Perforation of any duct within the biliary tree&#xD;
&#xD;
          -  Presence metallic biliary stent or bile duct surgery&#xD;
&#xD;
          -  Patients for whom PTC procedures are contraindicated&#xD;
&#xD;
          -  Patients with active hepatitis or intrahepatic metastases that extensively involves&#xD;
             both lobes of the liver&#xD;
&#xD;
          -  Noncooperation or no authorization and signature&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao-jun Teng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhong-Da Hospital, Southeast University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongda Hospital,Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Gao-Jun Teng</investigator_full_name>
    <investigator_title>Director of Department of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

